Ohio negotiates prize freeze on anti-overdose drug

State officials announced this week that Ohio is the first state to negotiate a price freeze with the maker of naloxone, an opiate overdose medication (Source: “Ohio locks in discount for overdose drug,” Chillicothe Gazette, Nov. 30, 2016)

Ohio is the only state to have secured a price freeze with Adapt Pharma, the only manufacturer of FDA-approved nasal naloxone, Narcan. When given to a person overdosing on opioids such as heroin, fentanyl, carfentanil or a prescription opioid, naloxone can limit or stop the overdose by reversing the effects of the opioid on the brain.

The price freeze applies to first responders, law enforcement and community-based organizations. The wholesale cost for two 4 mg doses of the nasal spray is $125, but Ohio agencies will be charged $75, a 40 percent discount.

Attorney General Mike DeWine worked with Adapt Pharma to negotiate a price freeze with hopes that by keeping costs down, more agencies will consider keeping naloxone on hand.

Attend HPIO's 2026 Health Policy Summit on Aug. 26

The Summit will draw insights from HPIO’s 2026 Health Value Dashboard to focus attention on the factors that drive population health and healthcare spending and build momentum for policy priorities that lead to improved health and well-being for Ohioans.

Register now